Meta-analysis and Meta-regression of Cognitive Behavioral Therapy for Psychosis (CBTp) Across Time: The Effectiveness of CBTp has Improved for Delusions

Katarzyna Sitko*, Bridgette M Bewick, David Owens, Ciara Masterson
Faculty of Medicine and Health, School of Medicine, University of Leeds, Leeds LS2 9JT, UK
*To whom correspondence should be addressed; tel: +44(0)113-343-0829, e-mail: ksitkok@gmail.com

Published research shows small-to-medium effects of Cognitive Behavioral Therapy for Psychosis (CBTp) on reducing psychotic symptoms. Given the on-going development of CBTp interventions, the aim of this systematic review is to examine whether the effectiveness of CBTp has changed across time. MEDLINE, EMBASE, PsycINFO, and CENTRAL were searched for randomized controlled trials examining CBTp interventions targeting positive and/or negative symptoms vs treatment as usual. Four meta-analyses were carried out to examine the effectiveness of CBTp for: positive symptoms; delusions; hallucinations; and negative symptoms. Four meta-regressions examined whether the effectiveness of CBTp changed across time for these groups of symptoms. A total of 28 studies (n = 2698) yielded a pooled g of -0.24 (95% confidence interval [CI] -0.32, -0.16, P < .001) favoring CBTp for positive symptoms, with nonsignificant heterogeneity (Q = 26.87, P = .47; F = 0%); 13 studies (n = 890) yielded a pooled g of -0.36 (95% CI -0.59, -0.13, P = .002) for delusions, with substantial heterogeneity (Q = 31.99, P = .001; F = 62%); 16 studies (n = 849) yielded a pooled g of -0.26 (95% CI -0.42, -0.11, P < .001) for hallucinations, with nonsignificant heterogeneity (Q = 18.10, P = .26; F = 17%); 19 studies (n = 1761) yielded a pooled g of -0.22 (95% CI -0.33, -0.12, P < .001) for negative symptoms, with nonsignificant heterogeneity (Q = 20.32, P = .32, F = 11%). Meta-regressions indicated a significant effect of year on the effectiveness of CBTp only for delusions (F[1, 11] = 5.99, P = .032; R² = 0.594); methodological quality did not affect this finding. Findings indicate small-to-medium effects of CBTp for psychotic symptoms, with increasing effectiveness across time for delusions.

Key words: psychosis/trauma/meta-analysis

Introduction
Over their lifetime, approximately 1% of the UK population will receive a diagnosis of schizophrenia. The complexity of this condition puts pressure on services to provide effective treatments. The National Institute for Care and Health Excellence (NICE) recommends Cognitive Behavior Therapy for Psychosis (CBTp) as one of the psychological treatments for psychosis. A recent meta-analysis reported that CBTp had small effects on psychotic symptoms, and the authors subsequently questioned whether CBTp should continue to be a recommended treatment. McKenna and Kingdon have similarly argued that CBTp has been “oversold” as a treatment for psychosis.

Meta-analyses have consistently reported small-to-moderate effects of CBTp on psychotic symptoms. One meta-analysis reported an effect of 0.25 for positive symptoms when CBTp was compared with a control intervention and an effect size of 0.31 when CBTp was compared with treatment as usual (TAU). When aspects of bias were considered, the effect sizes decreased. Another meta-analysis reported an effect size of 0.37 for positive symptoms, although, when methodological quality was taken into account, the effect size for the high-quality studies reduced and was 0.22 against 0.49 for the low-quality studies. A more recent meta-analysis found a small effect of 0.16 for positive symptoms favoring CBTp vs other psychological interventions.

Bentall proposed that examining individual psychotic symptoms, such as delusions and hallucinations, could be particularly helpful as it could lead to identifying symptom-specific psychological mechanisms that could be targeted in therapy. Steele et al similarly suggest that exploring the positive syndrome could lead to missing out on the multidimensional nature of individual symptoms. When types of positive symptoms were assessed separately, one meta-analysis found an effect size of 0.44
favoring CBTp for hallucinations and an effect size of 0.36 favoring CBTp for delusions when compared with the control group (TAU or an active control or a combination of both). Another meta-analysis found an effect size of 0.27 favoring CBTp for delusions when compared with TAU.

In terms of negative symptoms, one meta-analysis reported an effect size of 0.44 favoring CBTp, although, when the studies were divided by methodological quality, the effect size for the high-quality studies reduced and was 0.21 against 0.61 for the low-quality studies, once again pointing to the importance of considering methodological quality. Another meta-analysis reported particularly low effect sizes for CBTp on negative symptoms: 0.08 when compared with a control intervention and 0.13 when compared with TAU. As with positive symptoms, when aspects of bias were taken into consideration, the effect sizes decreased further. This low effect size may also reflect the focus of the clinical interventions. One meta-analysis, eg, found that most studies assessed negative symptoms as secondary treatment targets rather than primary targets. The authors argued that the clinical focus on positive symptoms, and the measurement of these as primary outcomes limits our understanding of the actual effect of CBTp targeting negative symptoms. Others have made similar claims, suggesting that cognitive-behavioral therapists have devoted more time to understanding and addressing positive symptoms. This focus could lead to a poorer understanding of negative symptoms and explain why they are usually the secondary outcomes in randomized controlled trials (RCTs).

As described above, meta-analytic reviews have shown differing effect sizes for the symptom-based outcomes, and difference in the methodological quality of trials has been shown to be important. Another likely reason for the variation is the difference in clinical focus between trials—some interventions target differing symptoms of psychosis, such as delusions or hallucinations. Another explanation for differences in effect sizes could be that clinical practice has evolved and that the delivery of CBTp has improved over time. Since the early trials of CBTp, the intervention has moved from challenging and disrupting the content of delusions and/or hallucinations to focusing on changing service users' relationship with their symptoms. This evolution reflects a theoretical shift: it is not the content of thoughts that need to be addressed but rather the interpretation of the thoughts (ie, meta-cognition). In addition to the evolution of CBTp, there have been advances in the understanding of the psychological mechanisms that could contribute to the formation, maintenance, and experience of psychotic symptoms: such as the role of emotion, arousal, self-esteem, attachment, interpersonal issues, and loss and trauma. Understanding these psychological mechanisms may permit more targeted treatment within the CBTp framework for service users, with their variety of personal histories, views of the world, and psychotic difficulties.

A recent meta-analysis examined whether the effectiveness of CBT for symptoms of depression changed across time. The authors found a decrease in effectiveness over time, where studies with earlier publication dates had larger effect sizes than more recent publications. The authors suggested that the declining treatment outcomes could be a reflection of the quality of the intervention, specifically the degree of clinician experience and the fidelity to the manual.

In psychosis research, there is a need to explore the effectiveness of CBTp across time, at least for positive symptoms. In a recent meta-analysis of negative symptoms, a meta-regression of the effects of CBTp was implemented by dividing the year of publication into four chronological clusters. The findings showed a decreasing effect, with better treatment outcomes for studies with an earlier publication date. The researchers also explored the impact of treatment focus and found that studies with strong behavioral interventions had larger effect sizes (Hedges' $g = 0.25$) compared with studies that had fewer behavioral components (Hedges' $g = 0.02$). They demonstrate a change in treatment over time; a shift away from the behavioral components reduced effect sizes, although they also found that higher quality trials were associated with lower effect sizes. This points to a need to consider trial quality as a factor when exploring change over time.

We carried out a systematic review of the effectiveness of CBTp across time, with separate analyses for positive symptoms, delusions, hallucinations, and negative symptoms; we also explored methodological quality. Our first hypothesis was that we would find an increase in the effectiveness of CBTp across time for positive symptoms and for hallucinations and delusions when these symptoms were assessed individually. Our second hypothesis was that there would not be an increase in the effectiveness of CBTp across time for negative symptoms.

Methods

Electronic searches of MEDLINE, EMBASE, PsycINFO, and CENTRAL were conducted on April 26, 2018 without a date restriction. Bibliographic references from previous meta-analytic reviews were manually searched for studies that may not have been identified by the search strategy, which is available in supplementary material S1.

Criteria for Study Inclusion/Exclusion

Studies included were parallel-group RCTs, single-blind RCTs, and open RCTs. Participants were those who experienced positive and/or negative symptoms from all mental health settings, including At-Risk-Mental-State (ARMS) participants. ARMS participants are at a preclinical stage and are considered at a higher risk of developing
psychosis than the general population. The inclusion criterion for the intervention group was individual or group CBTp or cognitive therapy (CT) that targeted positive or negative symptoms. The NICE guidelines and a description of the components of CBTp from a Delphi study were used in evaluating whether studies were delivering CBTp. If a study used other therapeutic elements, eg, family interventions, it was included if the CBTp was the predominant intervention. The inclusion criterion for the control group was TAU, which was conceptualized as the accepted usual treatment that was part of routine practice within the service where the RCT was delivered. Only outcomes that were researcher-rated at the end of treatment for positive or negative symptoms were included. Unless stated, it was assumed that the outcome measures were researcher-rated rather than client self-reported.

Unpublished studies and studies not in the English language were excluded. Studies including only children (under age 18) were excluded. Studies where participants had comorbid difficulties, such as recent history of violent behavior, cognitive impairment, or substance use, were also excluded. Studies were excluded if the intervention was integrative rather than predominantly CBTp. Studies were excluded if CBTp was compared with another intervention that was not considered TAU. Studies that described only self-reported outcomes were also excluded. A summary of the inclusion/exclusion criteria is available in supplementary material S2.

Methodological Quality and Bias
Since methodological quality of RCTs has been proposed as a possible source of funnel plot asymmetry, lower quality trials may show larger intervention effects compared with higher quality trials, the RCT-Psychotherapy Quality Rating Scale (RCT-PQRS) and the Cochrane Risk of Bias Tool were used to evaluate studies included in the meta-analysis.

The RCT-PQRS is a 25-item scale that assesses the quality of psychotherapies in RCTs. Items 1–24 are rated on a 0–2 Likert scale. A score of “0” reflects a poorly described and executed study design element; a score of “1” reflects a moderately described and executed study design element or a well described but poorly executed study design element or a poorly described but well executed study design element; and a score of “2” reflects a well justified, described, and executed study design element. Item 25, which is the omnibus quality rating of the whole study, is rated on a Likert scale from 1 to 7, where “1” reflects exceptionally poor quality and “7” reflects exceptionally good quality. All 25 items are grouped into six domains: description of subjects, definition and delivery of treatment, outcome measures, data analysis, treatment assignment, and overall quality of the study. To determine the omnibus quality rating (a score of 1–7) for each study, all subscales were averaged, then an overall average of the subscales was scaled on a 7-point rating scale; Cronbach’s $\alpha = .87$.

The Cochrane Risk of Bias Tool has five domains: selection bias, performance bias, attrition bias, reporting bias, and other bias. There are two parts to assessment within each domain item. First, the magnitude of risk of bias is judged as low, high, or unclear—using the guidance provided in the assessment tool. Second, text descriptions of the trial characteristics on which the judgments of risk of bias are based can be included to ensure transparency and to show support for the decision.

Stages of the Review and Meta-analysis
Author K.S. devised the search strategy with input from an information specialist. K.S. screened eligible studies twice to ensure that no studies were missed. Interrater reliability from a random selection of studies at the screening stage was calculated using ratings from another reviewer—S.R., a research assistant. Any disagreements between K.S. and S.R. were first discussed between themselves; if consensus was not reached authors, B.B. and C.M. were included in the discussion and a consensus decision was made. Data extraction including methodological quality and bias was carried out by K.S.. Interrater reliability for methodological quality and bias was calculated using S.R.’s ratings from a random selection of studies.

Data Analytic Plan
Effect sizes were computed using Review Manager (RevMan; version 5.3) using the random-effects model. The random-effects model assigns study weights, allowing studies that yield a more precise estimate to carry more importance. To examine whether the effectiveness of CBTp has improved over time for positive symptoms, delusions, hallucinations, and negative symptoms, four meta-regression analyses were carried out using the Statistical Package for the Social Sciences (SPSS; version 24) software. The linear regression analysis was selected using the year of publication as the independent variable and Hedges’ $g$ effect sizes from RevMan as the dependent variable. Higgins and Thompson proposed that a meta-regression should be weighted to take into account both within-study and between-studies variance. All meta-regressions used weights produced in RevMan, which were inserted into the “WLS weight” option in the linear regression.

Since Pickering et al proposed that co-occurring symptoms may confound predictors, hallucinations were adjusted for when examining delusions and vice versa in the additional analyses. As it can be argued that the methodological quality of RCTs assessing CBTp may have changed across time, additional analyses including methodological quality were implemented where we
found significant effect of year of publication on effect size. The methodological quality scores from the RCT-PQRS were entered into the linear regression to assess whether it confounded the relationship between the year of publication and the observed effect sizes and also to assess for moderation using the interaction term RCT-PQRS × YEAR.

Publication bias was examined using the Begg and Mazumdar’s Rank Order Correlation test, 32 Egger’s regression intercept test, 33 and Duval and Tweedie’s trim-and-fill procedure 34 using the Comprehensive Meta-Analysis software (version 3). 35

**Additional Analyses Undertaken**

Additional analyses were computed when examining the effects of CBTp for positive symptoms. The inclusion criteria included RCTs where participants experienced positive or negative symptoms. Trials that examined ARMS were, therefore, included. 36, 37 Since this population differs from those who have experienced first episode psychosis or recurrent psychosis, a separate meta-analysis was carried out excluding the two ARMS studies to examine whether this affected the observed pooled effect size. Two studies were self-guided and one was based on virtual reality (VR); another separate analysis was carried out excluding these three studies. 38–40 Finally, in terms of negative symptoms, one study used a scale that was not accessible, and we could, therefore, not be sure that it was measuring negative symptoms. 41 Although we excluded this study from the main analysis, we conducted a separate meta-analysis with it included to examine its impact on the pooled estimate.

**Results**

The systematic literature search produced 3451 titles. After the initial duplicate copies were removed, 2407 remained and were screened by title and abstract; 218 of these articles were included in the final screening phase yielding 29 studies that were eligible for analysis as shown in figure 1. These studies were published between 1998 and 2018.

**Additional Study Exclusions and Considerations**

One study was excluded because the outcomes were self-reported at baseline and researcher-rated at the end of treatment. 42 We considered that this lack of consistency could have affected outcomes. Another study reported only state paranoia scores—how the individual felt within the past 15 min. 43 We excluded this study because this method of measurement significantly deviated from the other included studies. In one study, two participants in the CT group and one in the TAU group self-reported at the end of treatment 44; this was included as the rest of the outcome data were researcher-rated. One study 45 was excluded because it did not report the end-of-treatment data, and we were unable to access those data from the authors. Several studies that focused on prioritizing other service user difficulties, such as anxiety or depression, 46 were excluded as not all participants received the same intervention. RCTs that delivered CBTp but only to service users who exhibited warning signs of potential relapse were also excluded as not all service users received the same intervention. 47

Several of the studies retrieved were based on the same data set. In cases where data could not be extracted from the original article because, eg, they were missing, incomplete, or presented in change scores, the article with the most complete statistical information was sought, although the original article was cited. 48, 49 Characteristics of the included studies are shown in table 1.

**Interrater Reliability**

From the initial 2407 titles, 406 (17%) were randomly selected for reliability testing. The agreement rate was

---

**Figure 1.** PRISMA diagram of the studies included in the meta-analysis.

---
| Author, year | Intervention group | Control group | Country | Method of delivery | Intervention length | Sessions offered | Sessions received | Targeted symptoms |
|-------------|--------------------|---------------|---------|-------------------|-------------------|-----------------|-----------------|-----------------|
| Tarrier 1998 | CBTp + TAU         | TAU           | United Kingdom | Individual       | 10 weeks          | 20 sessions     | Not recorded    | Positive; negative |
| Lewis 2002  | CBTp + TAU         | TAU           | United Kingdom | Individual       | 5 weeks           | 15–20 h + booster | Mean 16.1; 95% CI (15.2–17.1) | Positive; negative |
| Rector 2003 | CBTp + ETAU        | ETAU          | Canada      | Individual       | 26 weeks          | 20 sessions     | Not reported    | Positive; negative |
| Durham 2003 | CBTp + TAU         | TAU           | United Kingdom | Individual       | 39 weeks          | 20 sessions     | Mean 7.5; SD 6.4 | Positive; negative |
| Jolley 2003 | CT + TAU           | TAU           | United Kingdom | Individual       | 26 weeks          | 18 sessions     | Median 16      | Hallucinations (distress) |
| Trower 2004 | CT + TAU           | TAU           | United Kingdom | Individual       | 26 weeks          | Not reported    | Mean 12.9; SD 9.4 | Positive; negative |
| Startup 2004| CBTp + TAU         | TAU           | United Kingdom | Individual       | 26 weeks          | 25 sessions     | Mean 10.4; SD 6.5 | Positive |
| Barrowclough 2006 | CBTp + TAU         | TAU           | United Kingdom | Group           | 26 weeks          | 18 sessions     | Mean 14.4; SD 7.8 | Positive; negative |
| McLeod 2007 | CBTp + TAU         | TAU           | United Kingdom | Group           | 12 weeks          | 8 sessions      | Not reported    | Hallucinations |
| Lecomte 2008 | CBTp + TAU         | TAU           | United Kingdom | Group           | 13 weeks          | 24 sessions     | Not reported    | Positive; negative |
| Garety 2008 | CBTp + TAU         | TAU           | United Kingdom | Individual      | 52 weeks          | 12–20 sessions  | Mean 13.9; SD 8.0 | Positive; negative |
| no carer Garety 2008 | CBTp + TAU         | TAU           | United Kingdom | Individual      | 52 weeks          | 12 sessions     | Mean 11.93; SD 0.83 | Positive |
| Pinninti 2010| CBTp + TAU(SGA)    | TAU(SGA)      | United States | Individual      | 12 weeks          | 26 sessions     | Not reported    | Positive; negative |
| van Der Gaag 2011 | CBTp + TAU         | TAU           | Netherlands   | Individual      | 38 weeks          | 26 sessions     | Mean 28.9; SD 7.4 | Positive; negative |
| Lincoln 2012 | CBTp + TAU         | TAU           | Germany       | Individual      | 38 weeks          | 26 sessions + booster | Mean 9.11; SD 6.69 | Positive; negative |
| Morrison 2012 | CBTuhr + TAU +    | TAU + monitoring | United Kingdom | Individual      | 26 weeks          | 26 sessions + booster | Mean 9.11; SD 6.69 | Positive; negative |
| van der Gaag 2012 | CBTuhr + TAU       | TAU           | Netherlands   | Individual      | 26 weeks          | 26 sessions     | Mean 10        | Positive; negative |
| Rathod 2013  | CaCBT + TAU        | TAU           | United Kingdom | Individual      | 16–20 weeks       | 16 sessions     | Mean 13.6; SD 4.9 | Positive (distress) |
| Krakvik 2013 | CBTp + TAU         | TAU           | Norway        | Individual      | 17–26 weeks       | 20 sessions     | Not reported    | Positive (distress) |
| Morrison 2014| CBTp + TAU         | TAU           | United Kingdom | Individual      | 39 weeks          | 26 sessions + booster | Mean 13.3; SD 7.57 | Positive; negative |
| Birchwood 2014 | CBTp + TAU         | TAU           | United Kingdom | Individual      | 39 weeks          | 25 sessions     | Mean 19; SD 9   | Hallucinations (distress) |
| Naeem 2015  | CaCBT + FI + TAU   | TAU           | Pakistan      | Individual      | 17 weeks          | 6 sessions      | Not reported    | Positive; negative |
| Ruggeri 2015| CBTp + FI + TAU    | TAU           | Italy         | Individual      | 39 weeks          | CBTp: 20–30 sessions; FI 10–15 sessions | Not reported | Positive; negative |
We agreed to “exclude” 390 studies, “include” 5 studies, and “could not tell” for 2 of the studies. The disagreement rate was 2% with 2 ratings being “include” vs “exclude,” and 7 of the ratings being “cannot tell” vs “exclude.”

From the 29 studies included, 5 were randomly selected for interrater reliability ratings of the RCT-PQRS and the Cochrane Risk of Bias Tool. For the RCT-PQRS, Cohen's Kappa was \( \kappa = 0.62 \) and, for the Cochrane Risk of Bias, Cohen's Kappa was \( \kappa = 0.73 \). According to Landis and Koch's criteria, this represents a substantial level of agreement.50

**Meta-analyses and Meta-regressions**

**Positive Symptoms.** The analysis for positive symptoms included 2698 participants. The pooled effect size for the 28 studies examining positive symptoms was \(-0.24\) (95% CI \(-0.32, -0.16\), \(P < .001\)) (negative sign favors CBTp). These results indicated nonsignificant heterogeneity \((Q = 26.87, P = .47)\) with an \(I^2 = 0\%\). When the two ARMS studies were excluded, the pooled effect size for the 26 studies was \(-0.26\) (95% CI \(-0.34, -0.18\), \(P < .001\)). These results indicated nonsignificant heterogeneity \((Q = 24.78, P = .47)\), with an \(I^2 = 0\%\). Finally, when in addition to the ARMS studies, the one VR and two self-help studies were removed, the pooled effect size for the 23 studies was \(-0.26\) (95% CI \(-0.34, -0.17\), \(P < .001\)). These findings also indicate nonsignificant heterogeneity \((Q = 20.57, P = .55)\) with an \(I^2 = 0\%\). Since excluding the ARMS, VR, and self-help studies made little difference to the overall pooled effect size, all 28 studies were included in the final meta-analysis; the forest plot is shown in figure 2. A weighted meta-regression indicated no effect of year on the effectiveness of CBTp on positive symptoms, \(F(1,26) = 0.00, P = .996\), with an \(R^2 = 0.001\).

**Delusions.** When 15 out of the 28 studies that report a specific measure of delusions were analyzed, the pooled effect size for these studies was \(-0.34\) (95% CI \(-0.53, -0.14\), \(P < .001\)). These studies were heterogeneous \((Q = 32.80, P = .003)\) with an \(F = 57\%\). Within this meta-analysis, there were two studies that reported that they were targeting only hallucinations and not delusions. When these studies were removed, the pooled effect size for the 890 participants was \(-0.36\) (95% CI \(-0.59, -0.13\), \(P = .002\)), with substantial heterogeneity \((Q = 31.99, P = .001)\) with an \(F = 62\%\). The forest plot for these studies is shown in figure 2. A weighted meta-regression indicated a significant effect of year on the effectiveness of CBTp on delusions, \(F(1,11) = 5.99, P = .032\), with an \(R^2 = 0.594\). In this model, the year of publication, \(t(11) = -2.44, P = .032\), was a significant predictor of the effectiveness of CBTp on delusions, indicating that the effectiveness of CBTp increased with increasing year of publication. This finding persisted
when co-occurring hallucinations were controlled for, $F(2, 8) = 5.441$, $P = .032$, with an $R^2 = 0.759$, where the year of publication, $t(8) = 2.72$, $P = .026$, still significantly predicted CBTp effectiveness. This finding also persisted when methodological quality (RCT-PQRS) was controlled for as a confounding variable, $F(3, 7) = 13.34$, $P<.001$, $R^2 = .809$. Figure 2.

**Figure 2.** Forest plot of studies in the meta-analysis of positive symptoms, delusions, hallucinations, and negative symptoms, respectively.
$P = .003$, with an $R^2 = 0.923$, where the year of publication $t(7) = -4.29$, $P = .004$ continued to predict the effectiveness of CBTp on delusions. This finding suggests that methodological quality did not confound the relationship between year of publication and effectiveness. The interaction term between the methodological quality and year (RCT-PQRS × YEAR) was not significant, $F(1,11) = 3.67$, $P = .082$, with an $R^2 = 0.500$, suggesting that methodological quality did not moderate the relationship between the effectiveness of CBTp on delusions and year of publication.

**Hallucinations.** When studies that reported a score for hallucinations were taken into account, the pooled effect for the 849 participants in the 16 studies was $-0.26$ (95% CI $-0.33$, $-0.12$), $P < .001$. These studies indicated nonsignificant heterogeneity ($Q = 18.10$, $P = .26$) with an $I^2 = 17\%$. The forest plot for these studies is shown in figure 2. A weighted meta-regression indicated a nonsignificant effect of year on the effectiveness of CBTp on hallucinations $F(1,14) = 0.43$, $P = .522$, with an $R^2 = 0.173$. This finding was unchanged when co-occurring delusions were controlled for $F(2,8) = 1.67$, $P = .248$, with an $R^2 = 0.543$.

**Negative Symptoms.** When all studies that report negative symptoms were taken into account, the pooled effect for the 1761 participants in the 19 studies was $-0.22$ (95% CI $-0.33$, $-0.12$), $P < .001$. These studies were not heterogeneous ($Q = 20.32$, $P = .26$) with an $I^2 = 11\%$. The forest plot for these studies is shown in figure 2. A weighted meta-regression indicated a nonsignificant effect of year on the impact of CBTp on negative symptoms, $F(1,16) = 0.747$, $P = .400$, with an $R^2 = 0.211$.

**Publication Bias**

**Positive Symptoms.** For positive symptoms, Begg and Mazumdar’s test generated nonsignificant Kendall’s $\tau$ of $-0.18$ ($z = 1.32$; $P = .09$, one tailed). Egger’s test generated an intercept of $-0.80$ (95% CI $-1.79$, $0.19$; $t[26] = 1.65$; $P = .06$, one tailed), which reflects nonsignificance, suggesting that publication bias is not present. Duval and Tweedie’s trim and fill procedure, however, identified five potential missing studies and recomputed the new point estimate at $-0.14$ (95% CI $-0.27$, $-0.02$), which affected the overall magnitude of the effect size. All results of tests for publication bias are presented in table 2, with funnel plots in figure 3.

**Methodological Quality**

Ratings on the six domains of the Cochrane Risk of Bias were mainly low or unclear risk, and only a few studies were rated as high risk on certain domains.

**Discussion**

The aim of this systematic review and meta-analysis was to examine the effectiveness of CBTp for positive symptoms, delusions, hallucinations, and negative symptoms and to determine whether the effectiveness of CBTp changed across time. The results showed small-to-medium significant effects favoring CBTp for positive symptoms, hallucinations, delusions, and negative symptoms. We had hypothesized an increase in the effectiveness of CBTp over time for positive symptoms, delusions, and hallucinations, but this effect was only observed for delusions. We found that methodological quality did not affect this finding, suggesting that this well exist. Duval and Tweedie’s trim and fill procedure identified five potential missing studies and recomputed the new point estimate at $-0.20$ (95% CI $-0.29$, $-0.11$), which slightly affected the overall magnitude of the effect size.

**Delusions and Hallucinations.** Tests of publication bias for delusions and hallucinations were nonsignificant, suggesting that bias is not a major problem.

**Negative Symptoms.** For negative symptoms, Begg and Mazumdar’s test generated a significant Kendall’s $\tau$ of $-0.29$ ($z = 1.75$; $P = .04$, one tailed). Egger’s test generated an intercept of $-0.91$ (95% CI $-2.22$, $0.41$; $t[17] = 1.45$; $P = .08$, one tailed), which reflects nonsignificance, suggesting that publication bias is not present. Duval and Tweedie’s trim and fill procedure, however, identified five potential missing studies and recomputed the new point estimate at $-0.14$ (95% CI $-0.27$, $-0.02$), which affected the overall magnitude of the effect size. All results of tests for publication bias are presented in table 2, with funnel plots in figure 3.

### Table 2. Results of tests for publication bias for positive symptoms, delusions, hallucinations, and negative symptoms

| Symptoms       | Studies, $n$ | Effect size (95% CI) | Trim and fill | Begg and Mazumdar’s test $^b$ |
|----------------|-------------|----------------------|---------------|-------------------------------|
| Positive       | 28          | $-0.24$ (−0.32; −0.16) | $-0.20$ (−0.29; −0.11)$^a$ | $t$ $= 1.65$; $P = .06$; $z$ $= 1.32$; $P = .09$ |
| Delusions      | 13          | $-0.26$ (−0.42; −0.11) | None          | $P = .79$, $z = .21$ |
| Hallucinations | 16          | $-0.22$ (−0.33; −0.12) | None          | $P = .67$, $z = .25$ |
| Negative       | 19          | $-0.14$ (−0.27; −0.02)$^a$ | $t = 1.45$, $P = .08$, $z = 1.75$, $P = .04$ |

Note: $^a$Five studies were imputed. $^b$Tests were one-tailed.
improvement in treatment effectiveness is probably not a result of changes in trial quality.

In terms of positive symptoms, the pooled effect size indicated a small significant effect of 0.24, favoring CBTp over TAU. When publication bias was assessed, the effect reduced to 0.20. Our finding is similar to that of Jauhar et al who found an effect size of 0.24. Wykes et al found a small-to-medium effect size of 0.37 but, as discussed in Jauhar et al, the authors used Glass’s approach in calculating effect size, which has been purported to inflate the effect size. When positive symptoms were examined individually, the pooled effect size for delusions indicated a small-to-medium significant effect of 0.36 favoring CBTp and a pooled effect size of 0.26 for hallucinations. This suggests potential differences in the effect of CBTp on reduction of delusions and hallucinations and points to the importance of examining positive symptoms individually in future research.

In their recent meta-analysis assessing the effectiveness of CBTp on delusions, van der Gaag et al reported the same effect size of 0.36 favoring CBTp. In terms of hallucinations, Jauhar et al found an effect size of 0.34, while van der Gaag et al found an effect size of 0.44 favoring CBTp. The effect sizes in these meta-analyses are higher than our finding but an important difference is that these published meta-analyses included any comparison condition (ie, supportive counseling, TAU, and psychoeducation) and pooled data when there was more than one control group. The meaning of this difference is unclear; however, it would suggest that when CBTp is compared with an active comparison group, it appears more effective for hallucination symptoms in some of the studies. Unfortunately, the authors of these meta-analyses did not report the means and SDs; this restricts the making of comparisons between the studies and highlights the importance of future meta-analyses to provide these statistics as they may provide additional information that may be helpful in determining why such differences may exist.

In our systematic review, as in other reviews, the hallucination and delusion scores were averaged to generate a positive symptom score in studies that did not report an overall score. Since hallucinations and delusions correlate well with one another (r = .44), there is good justification for such a composite score. However, it has been reported that many people experience only delusions or only hallucinations; averaging these subscales in individuals who experience only one of these symptoms may lead to a deflated score as a result of the loss of important information in terms of severity when the scores are averaged. In this meta-analysis, examining psychotic symptoms individually was shown to be more informative and meaningful than exploring positive symptoms as a syndrome as suggested in previous research.
Why has the Effectiveness of CBTp Increased for Delusions but not for Hallucinations?

The main finding in this meta-analysis is that the effectiveness of CBTp increased for delusions but not for hallucinations or negative symptoms. It may be that the evolution in CBTp and developments in the understanding of the psychological mechanisms that contribute to the formation, maintenance, and experience of psychotic symptoms have led to the improved effectiveness of CBTp for delusions.

Some researchers propose that the focus of working with hallucinations is to change the relationship an individual has with their voices (by challenging the power and omnipotence of the voices), leading to a reduction in distress rather than to a reduction in frequency. Although they acknowledge that a reduction in distress might lead to a reduction in the frequency of hallucinations, they assert that this is not the focus of therapy. Since the current meta-analysis examined symptom reduction rather than distress reduction, we were unable to examine the effectiveness of CBTp on distress and whether there was improvement across time.

One of the main limitations of assessing the effectiveness of CBTp for delusions and hallucinations is that we did not always know what symptoms were targeted by the CBTp intervention. For example, only four studies in the hallucinations meta-analysis claimed to be targeting hallucinations only, while one study in the delusions meta-analysis claimed that it was specifically targeting paranoia. The rest of the studies either are not explicit in the symptom focus or they broadly state that they are targeting positive symptoms. Although the two meta-analyses carried out here explored the effectiveness of CBTp on specific symptoms, we do not know what proportion of these symptoms were targeted in each study. As a result, the interpretation of findings is difficult and, although delusions and hallucinations frequently co-occur, there are many people who experience one or the other. One study, eg, reported that delusions and hallucinations co-occurred on the Psychotic Symptom Rating Scale (PSYRATS) in 45% of the sample. The authors found that the mean score for individuals reporting hallucinations only was 27.6 (SD = 6.7) but when combined with the whole group, including those who did not report hallucinations, the mean was smaller 14.4 (SD = 14.6). This difference indicates the loss of important information in terms of severity when the whole group, including those who do not experience hallucinations, is averaged. For people reporting delusions only, the discrepancy in means is smaller: 16.3 (SD = 4.0), with a whole-sample mean of 13.5 (SD = 7.1). Averaging means for the whole sample, in cases where some participants do not experience hallucinations and where hallucinations were not the targeted intervention (even in those experiencing hallucinations), may be another reason why no increase in the effectiveness of CBTp for hallucinations was observed across time. Since we do not know what proportion of the intervention within the studies actually targeted hallucinations, the observed effect of CBTp for hallucinations may not be a true reflection of the actual effect of interventions targeting hallucinations specifically.

One of the main limitations of assessing negative symptoms in the current systematic review was that there was usually no information in the paper as to what proportion of therapy goals were targeting negative symptoms. In the current meta-analysis, there was only one study that focused on targeting negative symptoms. Since it is not certain whether the interventions in the studies included in the present meta-analysis actually targeted negative symptoms, the effect size observed (0.22) may not be a true reflection of the actual effect of targeted treatment. A distinction between primary or secondary negative symptoms would also have been helpful because, if a decrease in negative symptoms were observed, it could have been a result of a reduction in positive symptoms rather than through the direct targeted treatment of negative symptoms. This distinction is important as treatment for negative symptoms poses a major challenge for mental health services, and more effective treatments are needed. Velthorst et al reported similar findings to ours, an effect of 0.09 in favor of CBTp when negative symptoms were examined as secondary outcomes and an effect of 0.16 when negative symptoms were examined as primary outcomes.

Further Research

A closer examination of the studies in the current meta-analysis showed substantial variability in terms of manual use: some studies reported a manualized approach with adherence and fidelity ratings, others reported not using a manualized approach, while yet others reported amalgamating several different manuals. Morrison proposed that, in order to replicate outcomes, RCTs should show adherence and fidelity to the trial’s models and manualized protocol. This process might ascertain whether the RCTs are providing the treatment they set out to deliver. It could also help identify which models or manuals are associated with more effective outcomes. Furthermore, an assessment of long-term effectiveness using follow-up data could indicate whether effects persist, increase, or decrease with time.

Limitations

In addition to the limitations above, others need to be considered. First, the current meta-analyses only examined researcher-rated symptom outcomes. Previous research has shown poor correlations between service users’ subjective ratings and clinicians’ ratings of psychotic symptoms. It would, therefore, have been valuable to examine both ratings; however, since most
of the studies reported researcher-rated outcomes, this would have been a much smaller analysis. Second, the meta-analyses focused on clinical outcomes rather than any other outcome that might have been important to the service users, such as quality of life or subjective recovery. Since recovery in psychosis is a personally defined journey that is not always associated with symptom reduction, it would have been valuable to examine subjective recovery outcomes. Fortunately, there is a growing trend to include service user outcome measures and it may be possible for future reviewers to assimilate data from primary studies that report these items. Third, most studies included in the meta-analysis did not provide adherence ratings and the quality of the intervention, and adherence to the model is unknown. Fourth, length of treatment was not assessed, and the effect of treatment dosage is unknown. Fifth, the current meta-analyses examined data at the end of treatment. This limits our understanding whether the effects persist, increase, or decrease with time. Sixth, the effects of antipsychotic medication were not controlled for. Perhaps it was an evolution in antipsychotic medication that led to an increase in the effects of the observed CBTp rather than the effects of the evolution of CBTp. Although this could be the case, the TAU group usually included medication as one of the treatments, so this does not seem to be a plausible argument. It is plausible that the effect of antipsychotic medication was to help clients engage better in therapy, but this notion would need further examination.

Conclusion
The most recent National Clinical Audit of Psychosis reported that only 26% of service users were offered CBTp. The finding in the current meta-analysis suggests that CBTp can be effective at reducing psychotic symptoms and that the effectiveness of CBTp for delusions has increased over time. This finding is important because it challenges arguments that CBTp has been oversold. Instead, the clinical implications of this systematic review are that CBTp should continue to be offered as a psychological intervention to service users with psychosis, especially those experiencing delusions. On a final note, it is important to note that basing treatment decisions on meta-analytic findings can be difficult as the data rely on “average” outcomes and there are no “average” service users. Evidencing the efficacy of treatment on the outcomes that are important to service users (e.g., distress) seems an important next step.

Supplementary Material
Supplementary data are available at Schizophrenia Bulletin Open online.

Acknowledgments
We would like to thank Sarah Rudkin for her assistance with the reliability ratings.

Funding
No funding received.

Conflicts of Interest: The authors have declared that there are no conflicts of interest in relation to the subject of this study.

References
1. Royal College of Psychiatrists. Factsheet, schizophrenia: information for parents, carers and anyone who works with young people. 2017. https://www.rcpsych.ac.uk/mental-health/parents-and-young-people/information-for-parents-and-carers/schizophrenia-for-parents-and-carers. Accessed March 4, 2018.
2. National Institute for Care and Health Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. London, UK: NICE; 2014: 1–46. https://www.nice.org.uk/guidance/cg178/resources/schizophrenia-and-psychosis-in-adults-prevention-and-management-pdf-351075852133. Accessed March 8, 2018.
3. Jauhar S, McKenna P, Radua J, Fung E, Salvador R, Laws K. Cognitive–behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014;204:20–29.
4. McKenna P, Kingdon D. Has cognitive behavioural therapy for psychosis been oversold? BMJ. 2014;348:g2295.
5. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523–537.
6. Turner DT, van der Gaag M, Karyotaki E, Cuijpers P. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014;171:523–538.
7. Bentall RP. Madness Explained: Psychosis and Human Nature. London, UK: Penguin; 2004.
8. Steel C, Garety PA, Freeman D, et al. The multidimensional measurement of the positive symptoms of psychosis. Int J Methods Psychiatr Res. 2007;16:88–96.
9. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored formulation-based cognitive behavioural therapy in auditory hallucinations and delusions: a meta-analysis. Schizophr Res. 2014;156:30–37.
10. Mehl S, Werner D, Lincoln TM. Does cognitive behavior therapy for psychosis (CBTp) show a sustainable effect on delusions? A meta-analysis. Front Psychol. 2015;6:1450.
11. Velthorst E, Koeter M, van der Gaag M, et al. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychiatr Med. 2015;45:453–465.
12. Morrison A, Renton J, Dunn H, Williams S, Bentall R. Cognitive Therapy for Psychosis: A Formulation-Based Approach. East Sussex, UK: Routledge; 2004.
13. Tai S, Turkington D. The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments. Schizophr Bull. 2009;35:865–873.
14. Freeman D, Garety PA. Connecting neurosis and psychosis: the direct influence of emotion on delusions and hallucinations. Behav Res Ther. 2003;41:923–947.
15. Morrison AP, Wells A. A comparison of metacognitions in patients with hallucinations, delusions, panic disorder, and non-patient controls. Behav Res Ther. 2003;41:251–256.
16. Barrowclough C, Tarrier N, Humphreys L, Ward J, Gregg L, Andrews B. Self-esteem in schizophrenia: relationships between self-evaluation, family attitudes, and symptomatology. J Abnorm Psychol. 2003;112:92–99.
17. MacBeth A, Schwannauer M, Gumley A. The association between attachment style, social mentalities, and paranoid ideation: an analogue study. Psychol Psychother. 2008;81(Pt 1):79–93.
18. Birchwood M, Meaden A, Trower P, Gilbert P, Plaistow J. The power and omnipotence of voices: subordination and entrapment by voices and significant others. Psychol Med. 2000;30:337–344.
19. Read J, Perry BD, Moskowitz A, Connolly J. The contribution of early traumatic events to schizophrenia in some patients: a traumagenic neurodevelopmental model. Psychiatry. 2001;64:319–345.
20. Velligan DI. Cognitive behavior therapy for psychosis: where have we been and where are we going? Schizophr Bull. 2009;35:857–858.
21. Johnsen TJ, Friborg O. The effects of cognitive behavioral therapy as an anti-depressive treatment is falling: a meta-analysis. Psychol Bull. 2015;141:747–768.
22. Morrison AP, Barratt S. What are the components of CBT for psychosis? A Delphi study. Schizophr Bull. 2010;36:136–142.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
24. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412.
25. Kocsis JH, Gerber AJ, Milrod B, et al. A new scale for assessing the quality of randomized clinical trials of psychotherapy. Compr Psychr. 2010;5:319–324.
26. Higgins JP, Altman DG, Gotzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
27. Cochrane Collaboration. Review manager (RevMan) [computer program]. Version 5.3. 2014. https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download. Accessed January 7, 2019.
28. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111.
29. IBM Corp. IBM SPSS Statistics: Version 24. Chicago, IL: IBM Corporation Chicago; 2017.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
31. Pickering L, Simpson J, Bentall RP. Insecure attachment predicts proneness to paranoia but not hallucinations. Pers Individ Diff. 2008;44:1212–1224.
32. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
34. Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.
35. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis, Version 3. Englewood, NJ: Biostat; 2013.
36. Morrison AP, French P, Stewart SL, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ. 2012;344:e2233.
37. van der Gaag M, Nieman DH, Rietdijk J, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. 2012;38:1180–1188.
38. Gottlieb JD, Gidugu V, Maru M, et al. Randomized controlled trial of an internet cognitive behavioral skills-based program for auditory hallucinations in persons with psychosis. Psychiatr Rehabil J. 2017;40:283–292.
39. Naeem F, Johal R, McKenna C, et al. Cognitive behavior therapy for psychosis based guided self-help (CBT-p-GSH) delivered by frontline mental health professionals: Results of a feasibility study. Schizophr Res. 2016;173:69–74.
40. Pot-Kolder RMCA, Geraets CNW, Veling W, et al. Virtual-reality-based cognitive behavioural therapy versus waiting list condition for paranoid ideation and social avoidance in patients with psychotic disorders: a single-blind randomised controlled trial. Lancet Psychiatry. 2018;5:217–226.
41. Rathod S, Phiri P, Harris S, et al. Cognitive behaviour therapy for psychosis can be adapted for minority ethnic groups: a randomised controlled trial. Schizophr Res. 2013;143:319–326.
42. Hazell CM, Hayward M, Cavanagh K, Jones AM, Strauss C. Guided self-help cognitive-behaviour Intervention for VoicEs (GiVE): results from a pilot randomised controlled trial in a transdiagnostic sample. Schizophr Res. 2018;195:441–447.
43. Waller H, Emsley R, Freeman D, et al. Thinking well: a randomised controlled feasibility study of a new CBT therapy targeting reasoning biases in people with distressing persecutory delusional beliefs. J Behav Ther Exp Psychiatry. 2015;48:82–89.
44. Jolley S, Garety P, Craig T, Dunn G, White J, Aitken M. Cognitive therapy in early psychosis: a pilot randomised controlled trial. Behav Cogn Psychother. 2003;31:473–478.
45. Habib N, Dawood S, Kingdon D, Naeem F. Preliminary evaluation of culturally adapted CBT for psychosis (CA-CBTp): findings from developing culturally-sensitive CBT project (DCCP). Behav Cogn Psychother. 2015;43:200–208.
46. Peters E, Landau S, McCrone P, et al. A randomised controlled trial of cognitive behaviour therapy for psychosis in a routine clinical service. Acta Psychiatr Scand. 2010;122:302–318.
47. Gumley A, O’Grady M, McNay L, Reilly J, Power K, Norrie J. Early intervention for relapse in schizophrenia: results of a 12-month randomised controlled trial of cognitive behaviour therapy. Psychol Med. 2003;33:419–431.
48. Lecomte T, Leclerc C, Corbière M, Wykes T, Wallace CJ, et al. A new scale for assessing the quality of randomised controlled trials of cognitive-behaviour therapy in early psychosis: an analogue study. Schizophr Res. 2008;81(Pt 3):575–581.
49. Tarrier N, Yusupoff L, Kinney C, et al. Randomised controlled trial of intensive cognitive behaviour therapy.
therapy for patients with chronic schizophrenia. *BMJ.* 1998;317:303–307.

50. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics.* 1977;33:159–174.

51. Bentall RP, de Sousa P, Varese F, *et al.* From adversity to psychosis: pathways and mechanisms from specific adversities to specific symptoms. *Soc Psychiatry Psychiatr Epidemiol.* 2014;49:1011–1022.

52. Sitko K, Bentall RP, Shevlin M, O’Sullivan N, Sellwood W. Associations between specific psychotic symptoms and specific childhood adversities are mediated by attachment styles: an analysis of the National Comorbidity Survey. *Psychiatry Res.* 2014;217:202–209.

53. Varese F, Smeets F, Drukker M, *et al.* Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. *Schizophr Bull.* 2012;38:661–671.

54. Birchwood M, Spencer E. Psychotherapies for schizophrenia: a review. In: Maj M, Sartorius N, eds. Schizophrenia. WPA Series: Evidence and Experience in *Psychiatry.* Vol 2. Chichester, UK: John Wiley & Sons, Inc.; 1999:147–214.

55. Velligan DI, Roberts D, Mintz J, *et al.* A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia. *Schizophr Res.* 2015;165:175–180.

56. Staring AB, Ter Huurne MA, van der Gaag M. Cognitive behavioral therapy for negative symptoms (CBT-n) in psychotic disorders: a pilot study. *J Behav Ther Exp Psychiatry.* 2013;44:300–306.

57. Morrison AP. A manualised treatment protocol to guide delivery of evidence-based cognitive therapy for people with distressing psychosis: learning from clinical trials. *Psychosis.* 2017;9:271–281.

58. Morrison AP, Shryane N, Beck R, *et al.* Psychosocial and neuropsychiatric predictors of subjective recovery from psychosis. *Psychiatry Res.* 2013;208:203–209.

59. Anthony WA. Recovery from mental illness: the guiding vision of the mental health service system in the 1990s. *Psychosoc Rehabil J.* 1993;16:11–23.

60. Royal College of Psychiatrists. *National Clinical Audit of Psychosis—National Report for the Core Audit 2018.* London, UK: Healthcare Quality Improvement Partnership; 2018.